Delhi High Court Restores Government Ban on Fixed-Dose Diabetes Drug Combinations
The Delhi High Court upheld the government's ban on two specific fixed-dose combination drugs for Type II diabetes treatment, ruling that the Centre has authority to prohibit manufacturing and sale in public health interest. The court set aside a previous single-judge order and confirmed that regulatory action can be taken based on potential health risks without requiring proof of actual harm.
*this image is generated using AI for illustrative purposes only.
The Delhi High Court has restored the government ban on two specific fixed-dose combination (FDC) drugs for Type II diabetes treatment, marking a significant regulatory development in the pharmaceutical sector. In an order dated January 9, a Division Bench of Justices Anil Kshetarpal and Harish Vaidyanathan Shankar ruled that the Centre had the powers to stop manufacturing and sale of these medicines in the interest of public health.
Court's Ruling and Legal Framework
The Division Bench set aside a single-judge's order that had previously struck down the government's notifications, after which the Union government challenged the decision. The court ruled that under Section 26A of the Drugs and Cosmetics Act, 1940, the Centre is not required to establish actual or proven harm to human beings. A ban can be imposed if there is a likelihood that the drug poses a risk to human health.
Specific Drug Formulations Banned
The government had issued notifications in 2018 prohibiting the manufacturing and sale of two specific FDC formulations:
| Banned Formulation: | Composition |
|---|---|
| Type 1: | Glimepiride 1 mg/2 mg + Pioglitazone 15 mg/15 mg + Metformin 850 mg/850 mg |
| Type 2: | Glimepiride 1 mg/2 mg/3 mg + Pioglitazone 15 mg/15 mg/15 mg + Metformin 1000 mg/1000 mg |
Impact on Pharmaceutical Companies
This regulatory decision affects multiple pharmaceutical companies that manufacture these combination medications for diabetes treatment:
| Company: | Impact |
|---|---|
| Lupin | Fixed dose combination products affected |
| Eris Life Sciences | Diabetes treatment portfolio impacted |
| Sun Pharma | FDC products for Type 2 diabetes banned |
Regulatory Implications
The Delhi High Court's decision reinforces the government's authority to regulate pharmaceutical products in the interest of public health. The ruling emphasizes that regulatory action can be taken based on potential risk assessment rather than requiring proof of actual harm. This development underscores the evolving regulatory landscape in India's pharmaceutical sector and the emphasis on drug safety and efficacy standards.
The affected companies will need to reassess their diabetes treatment offerings and potentially focus on individual drug formulations or develop new combination products that comply with regulatory requirements.
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
